

Marion Eveillard

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1056100/publications.pdf>

Version: 2024-02-01

50
papers

273
citations

1305906

8
h-index

1113639

15
g-index

50
all docs

50
docs citations

50
times ranked

627
citing authors

#	ARTICLE	IF	CITATIONS
1	Letter to the editor with regard to the article entitled "Automated leukocyte parameters are useful in the assessment of myelodysplastic syndromes". <i>Cytometry Part B - Clinical Cytometry</i> , 2022, 102, 76-76.	0.7	0
2	Interference in platelet count due to microspherocytosis related to extensive burn injury. <i>International Journal of Laboratory Hematology</i> , 2022, 44, 57-58.	0.7	0
3	Hemophagocytic lymphohistiocytosis, what about hair?. <i>American Journal of Hematology</i> , 2022, 97, 508-509.	2.0	0
4	Extensive myelitis with eosinophilic meningitis after Chimeric antigen receptor T cells therapy. <i>EJHaem</i> , 2022, 3, 533-536.	0.4	2
5	Suffering neutrophils where is the enemy?. <i>International Journal of Laboratory Hematology</i> , 2022, 44, 806-807.	0.7	0
6	Lineage switch and relapse in sanctuary site: Some lessons to learn about plasticity in acute leukemia. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29683.	0.8	0
7	Strike while the iron is hot: diagnosis of pediatric idiopathic pulmonary hemosiderosis. <i>Blood</i> , 2022, 139, 2411-2411.	0.6	1
8	Dramatic Recovery after Etoposide Phosphate Infusion for Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome following Treatment with Tisagenlecleucel in a Young Patient with Relapsed Acute Lymphoblastic Leukemia: A Case Report. <i>Acta Haematologica</i> , 2022, 145, 537-541.	0.7	5
9	Therapeutic targets in childhood acute lymphoblastic leukemia: what about HER2/neu?. <i>Hematological Oncology</i> , 2021, 39, 270-272.	0.8	1
10	Fortuitous discovery of an NPM1 mutation in a myelodysplastic syndrome. <i>International Journal of Laboratory Hematology</i> , 2021, 43, 1258-1259.	0.7	0
11	Using MALDI-TOF mass spectrometry in peripheral blood for the follow up of newly diagnosed multiple myeloma patients treated with daratumumab-based combination therapy. <i>Clinica Chimica Acta</i> , 2021, 516, 136-141.	0.5	7
12	Deleterious neurological impact of diagnostic delay in immune-mediated thrombotic thrombocytopenic purpura. <i>PLoS ONE</i> , 2021, 16, e0260196.	1.1	3
13	A Prospective Phase 2 Study Testing High Dose Post-Transplant Cyclophosphamide As Sole Graft Prophylaxis after Matched Allograft Using Baltimore-Based Reduced-Intensity Conditioning Regimens and PBSC As Source of Graft. <i>Blood</i> , 2021, 138, 1812-1812.	0.6	1
14	Identification of gamma heavy chain disease using MALDI-TOF mass spectrometry. <i>Clinical Biochemistry</i> , 2020, 77, 57-61.	0.8	3
15	Antithymocyte globulin administration in patients with profound lymphopenia receiving a PBSC purine analog/busulfan-based conditioning regimen allograft. <i>Scientific Reports</i> , 2020, 10, 15399.	1.6	3
16	Flow cytometry in the diagnosis of mature cell lymphoproliferative disorders. <i>International Journal of Laboratory Hematology</i> , 2020, 42, 113-120.	0.7	11
17	Comparison of MALDI-TOF mass spectrometry analysis of peripheral blood and bone marrow-based flow cytometry for tracking measurable residual disease in patients with multiple myeloma. <i>British Journal of Haematology</i> , 2020, 189, 904-907.	1.2	40
18	Good IgA Bad IgG in SARS-CoV-2 Infection?. <i>Clinical Infectious Diseases</i> , 2020, 71, 897-898.	2.9	23

#	ARTICLE	IF	CITATIONS
19	Therapeutic Targets in Childhood B-Acute Lymphoblastic Leukemia : What about HER2/Neu?. Blood, 2020, 136, 15-16.	0.6	0
20	Absence of Influence of the Pre-Transplant Immune Status of Recipients on Survivals and Gvhd after Allogeneic Stem Cell Transplantation: A Retrospective Study of 195 Cases. Blood, 2020, 136, 2-3.	0.6	0
21	FLT3 ligand plasma levels have no impact on outcomes after allotransplant in acute leukemia. Cytokine, 2019, 120, 85-87.	1.4	1
22	Early (Day 15 Post Diagnosis) Peripheral Blood Assessment of Measurable Residual Disease in Flow Cytometry is a Strong Predictor of Outcome in Childhood B-Cell Lineage Lymphoblastic Leukemia. Cytometry Part B - Clinical Cytometry, 2019, 96, 128-133.	0.7	6
23	A new case of heterozygous variant of the <i>GP1BB</i> gene responsible for macrothrombocytopenia. British Journal of Haematology, 2019, 186, 157-159.	1.2	4
24	Prognostic Value of Lymphopenia and Lymphocytosis after Peripheral Blood Haplo-Identical Stem Cell Transplantation. Blood, 2019, 134, 3319-3319.	0.6	0
25	Profound Lymphopenia at the Time of ATG Administration Is Not Predictive of Survivals after Allogeneic Transplant Using Purine Analogue/Busulfan-Based Conditioning Regimen. Blood, 2019, 134, 1985-1985.	0.6	0
26	Multicentric Real Life Evaluation of the Impact of Next-Generation Sequencing on the Clinical Management of Chronic Myeloid Malignancies. Blood, 2019, 134, 5771-5771.	0.6	0
27	A blueberry muffin rash at birth. British Journal of Haematology, 2018, 182, 168-168.	1.2	1
28	CD200 expression in flow cytometry helps to distinguish mantle cell lymphoma from other CD5-positive B-cell neoplasms. Hematological Oncology, 2018, 36, 607-609.	0.8	7
29	Diagnosis of a lymphoma associated with human herpes virus 8 aided by flow cytometric immunophenotyping. British Journal of Haematology, 2018, 180, 471-471.	1.2	0
30	A new approach for diagnosing chronic myelomonocytic leukemia using structural parameters of Sysmex XN-TM analyzers in routine laboratory practice. Scandinavian Journal of Clinical and Laboratory Investigation, 2018, 78, 159-164.	0.6	14
31	Emergence and evolution of TP53 mutations are key features of disease progression in myelodysplastic patients with lower-risk del(5q) treated with lenalidomide. Haematologica, 2018, 103, e143-e146.	1.7	41
32	A clandestine worm. Blood, 2018, 131, 1493-1493.	0.6	0
33	A novel complete blood count-based score to screen for myelodysplastic syndrome in cytopenic patients. British Journal of Haematology, 2018, 183, 736-746.	1.2	15
34	Evaluation of minimal residual disease in childhood ALL. International Journal of Laboratory Hematology, 2018, 40, 104-108.	0.7	3
35	No Influence of Peripheral Blood CD34+ and CD3+ Graft Cell Counts on Outcomes after Reduced-Intensity Conditioning Transplantation Using Post-Transplant Cyclophosphamide. Blood, 2018, 132, 4577-4577.	0.6	0
36	Major impact of an early bone marrow checkpoint (day 21) for minimal residual disease in flow cytometry in childhood acute lymphoblastic leukemia. Hematological Oncology, 2017, 35, 237-243.	0.8	4

#	ARTICLE	IF	CITATIONS
37	Giant granule and platelets.... Blood, 2017, 129, 3043-3043.	0.6	0
38	IgM myeloma: A multicenter retrospective study of 134 patients. American Journal of Hematology, 2017, 92, 746-751.	2.0	45
39	Acquired elliptocytosis in the setting of a refractory anemia with excess blasts and del(20q). Blood, 2016, 127, 2646-2646.	0.6	8
40	Acute myeloid leukemia with erythrophagocytosis indicative of KAT6A rearrangement. Blood, 2016, 128, 314-314.	0.6	5
41	A deceiving cytopenia. Blood, 2016, 128, 2105-2105.	0.6	0
42	CD38 Expression in B-Lineage Acute Lymphoblastic Leukemia, a Possible Target for Immunotherapy. Blood, 2016, 128, 5268-5268.	0.6	5
43	Interest of the XN-10Â® Analyzer to Screen for Myelodysplastic Syndromes on Complete Blood Count (CBC) Especially with Hemoglobin Levels and Neut-WX. Blood, 2016, 128, 5518-5518.	0.6	3
44	IgM Myeloma: A Multicenter Retrospective Study of 159 Patients. Blood, 2016, 128, 3276-3276.	0.6	0
45	Polymorphonuclears Display a New Type of Abnormal Cytologic Granules (Chediak Higashi-Like) in a Very Rare Syndrome Linked to a Biallelic Defect of WDR81. Blood, 2016, 128, 1331-1331.	0.6	0
46	Comparative Value of the Assessment of Minimal Residual Disease in Peripheral Blood at Days 8 and 15 By Flow Cytometry in Childhood Acute Lymphoblastic Leukemia. Blood, 2016, 128, 5270-5270.	0.6	1
47	The closely related rare and severe acute myeloid leukemias carrying EVI1 or PRDM16 rearrangements share singular biological features. Haematologica, 2015, 100, e114-e115.	1.7	7
48	Post-Transplant Cyclophosphamide (PTCY) Versus Anti-Thymoglobulin (ATG) As Part of the Gvhd Prophylaxis for Fludarabine/Clofarabine/Busulfan Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT): Influence on Early Outcomes. Blood, 2015, 126, 4339-4339.	0.6	0
49	Expansion of T or B Lymphocytes after Unrelated Cord Blood (UCB) Allogeneic Stem Cell Transplantation in Adults Correlates with CMV Reactivation and Is Associated with a Better Outcome. Blood, 2015, 126, 1947-1947.	0.6	0
50	Prognostic Impact of Bone Marrow B Lymphocyte Precursors (hematogones) Detection in 95 Acute Lymphoblastic Leukemia Cases. Blood, 2012, 120, 4791-4791.	0.6	3